Niuhuang Jiedu tablets, anti-viral oral liquid and other drugs were inspected
On June 12, the Zhejiang Provincial Food and Drug Administration issued the first phase of the 2020 Zhejiang Province Drug Quality Inspection and Announcement (hereinafter referred to as "announcement").
The announcement pointed out that the bureau has recently organized and carried out random sampling inspections of the relevant drug quality of the drug production, operation and use units within its jurisdiction. During the inspection, it was found that 48 batches of drugs did not comply with the regulations.
Among them, 8 batches are preparations and 40 batches are decoction pieces. Among the 48 batches of drugs, Kudiezi injection produced by Shenyang Shuangding Pharmaceutical Co., Ltd. and Fabanxia produced by Anhui Xiehecheng Pharmaceutical Pieces Co., Ltd. all had re-inspection results in compliance with the regulations. This also means that the product quality problem is not a production quality problem of the production enterprise, and the quality problem may appear in other links such as circulation, transportation or storage.
In addition, it should be noted that there are many commonly used drugs in these 48 batches of drugs, including Yupingfeng oral liquid, Niuhuang Jiedu tablets, antiviral oral liquid, compound paracetamol tablets, Guizhi Fuling pills, Banlangen, honeysuckle...
For the above unqualified drugs, the bureau requires that, based on the measures that have been taken, all localities should further check and dispose of drugs and related units that do not meet the standards, effectively eliminate hidden dangers, and ensure the quality and safety of drugs.
Looking for chemical products? Let suppliers reach out to you!
2026-06-07
-
Life Science Ingredients Industry Overview
This issue offers a deep exploration of the evolving pharmaceutical and nutrition landscape, combining data, analysis, and insight to reveal key industry shifts and emerging directions. Support online permanent download.Published in: Nov. 2025
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Trump Plans 25% Tariffs on Autos, Drugs and Semiconductor Chips
-
ECHEMI平台投诉处罚规则 - ECHEMI platform complaint penalty rules
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
Ministry of Industry and InformationTechnology: 14 initiatives to help SMEs digital transformation
-
Jiangsu: Special graphite new material production project landed in Suyin Industrial Park
-
Guide to digital transformation of smalland medium-sized enterprises issued
-
Henan Province issued chemical parkconstruction standards and identified management methods
-
German丨Minister of Agriculture confirms plans to ban pesticide exports
-
EU丨Commission adopts new rules to fastrack approval of biological pesticides
Recommend Reading
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Notice of 2026 Chinese New Year Holiday
-
“The 40-Year Ethylene Giant Collapses”: ExxonMobil’s Premature Shutdown Is Not Just Scotland’s Tragedy—It’s the Twilight Elegy of European Industrial Civilization
-
Huntsman’s Rotterdam MDI Line Stumbles—$10M EBITDA Hit Sends Q4 Guidance to the Low End
-
IMCD to Expand Lubrizol’s Medical Solutions in North America
-
Polyethylene Weakens with Fluctuations, Trading Remains Light Before the Chinese New Year